Aurobindo Pharma Needs To Clear ₹1,250 For Fresh Rally Or May Slide To ₹1,050: SEBI RA Manish Kushwaha

Aurobindo Pharma shares traded 1% higher on Tuesday despite a slight dip in its fourth-quarter profits to ₹903 crore. 

Revenues rose 11% to ₹8,382 crores, and margins improved sequentially to 21.4%. 

On an earnings conference call, the management guided for high single-digit revenue growth in FY26. 

On the technical front, SEBI-registered analyst Manish Kushwaha advises caution. He highlighted that Aurobindo’s weekly chart is currently at a critical confluence zone. 

The price action shows a series of lower highs, indicating a broad distribution phase. 

He added that attempts at recovery have been met with consistent rejections near the descending trendline, as seen by multiple bearish wicks and reversal candles. 

Currently, the stock is hovering around the 38.2% Fibonacci retracement level (approximately ₹1,180), which is acting as a significant support-turned-resistance zone. 

The Relative Strength Index (RSI 14) stands around 48.57, suggesting neutral to slightly bearish momentum, as it remains below the 50 mark.

Kushwaha identified key levels for traders to watch: A breakdown below ₹1,180 could lead to a decline towards ₹1,050 or lower. 

On the other hand, a breakout above ₹1,250, supported by volumes, could set the stage for a rally till ₹1,450. 

Data on Stocktwits shows that retail sentiment turned ‘bullish’ on this counter a week ago.

Aurobindo Pharma shares have fallen 11% year-to-date (YTD).

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on